NVO 6-K
Novo Nordisk A S (NVO)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
February 6, 2025
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F ☒ | Form 40-F ☐ |
|---|
Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 6 February 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
Novo Nordisk A/SInvestor RelationsNovo Allé 12880 BagsværdDenmarkTelephone:+45 4444 8888www.novonordisk.com
CVR no: 24 25 67 90Company announcement No 8 / 2025
| 1 | Details<br>of the person discharging managerial responsibilities/person closely associated | ||||
|---|---|---|---|---|---|
| a) | Name<br>of the Board member/Executive/Associated Person | Liselotte<br>Sofie Hyveled | |||
| 2 | Reason<br>for the notification | ||||
| a) | Position/status | Member<br>of the Board of Directors | |||
| b) | Initial<br>notification/Amendment | Initial<br>notification | |||
| 3 | Details<br>of the issuer | ||||
| a) | Name | Novo<br>Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details<br>of the transaction(s) | ||||
| a) | Description<br>of the financial instrument,<br><br>type<br>of instrument, | Shares | |||
| Identification<br>code | Novo<br>Nordisk B DK0062498333 | ||||
| b) | Nature<br>of the transaction | Other<br>transaction (transfer of shares in<br><br>accordance<br>with Long Term Incentive programme) | |||
| c) | Price(s)<br>and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK<br>0.00 | 1,407<br>shares | ||||
| d) | Aggregated<br>information<br><br>·<br>Aggregated volume<br><br>·<br>Price | 1,407<br>shares<br><br>DKK<br>0.00 | |||
| e) | Date<br>of the transaction | 2025-02-05 | |||
| f) | Place<br>of the transaction | Outside<br>a trading venue |
Novo Nordisk A/SInvestor RelationsNovo Allé 12880 BagsværdDenmarkTelephone:+45 4444 8888www.novonordisk.com
CVR no: 24 25 67 90Company announcement No 8 / 2025
| 1 | Details<br>of the person discharging managerial responsibilities/person closely associated | ||||
|---|---|---|---|---|---|
| a) | Name<br>of the Board member/Executive/Associated Person | Lars<br>Fruergaard Jørgensen | |||
| 2 | Reason<br>for the notification | ||||
| a) | Position/status | President<br>and CEO | |||
| b) | Initial<br>notification/Amendment | Initial<br>notification | |||
| 3 | Details<br>of the issuer | ||||
| a) | Name | Novo<br>Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details<br>of the transaction(s) | ||||
| a) | Description<br>of the financial instrument,<br><br>type<br>of instrument, | Shares | |||
| Identification<br>code | Novo<br>Nordisk B DK0062498333 | ||||
| b) | Nature<br>of the transaction | Other<br>transaction (transfer of shares in<br><br>accordance<br>with Long Term Incentive programme) | |||
| c) | Price(s)<br>and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK<br>0.00 | 98,702<br>shares | ||||
| d) | Aggregated<br>information<br><br>·<br>Aggregated volume<br><br>·<br>Price | 98,702<br>shares<br><br>DKK<br>0.00 | |||
| e) | Date<br>of the transaction | 2025-02-05 | |||
| f) | Place<br>of the transaction | Outside<br>a trading venue |
Novo Nordisk A/SInvestor RelationsNovo Allé 12880 BagsværdDenmarkTelephone:+45 4444 8888www.novonordisk.com
CVR no: 24 25 67 90Company announcement No 8 / 2025
| 1 | Details<br>of the person discharging managerial responsibilities/person closely associated | ||||
|---|---|---|---|---|---|
| a) | Name<br>of the Board member/Executive/Associated Person | Lars<br>Fruergaard Jørgensen | |||
| 2 | Reason<br>for the notification | ||||
| a) | Position/status | President<br>and CEO | |||
| b) | Initial<br>notification/Amendment | Initial<br>notification | |||
| 3 | Details<br>of the issuer | ||||
| a) | Name | Novo<br>Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details<br>of the transaction(s) | ||||
| a) | Description<br>of the financial instrument,<br><br>type<br>of instrument, | Shares | |||
| Identification<br>code | Novo<br>Nordisk B DK0062498333 | ||||
| b) | Nature<br>of the transaction | Sale<br>of shares | |||
| c) | Price(s)<br>and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| 618.10<br>DKK | 32<br>shares | ||||
| d) | Aggregated<br>information<br><br>·<br>Aggregated volume<br><br>·<br>Price | 32 shares<br><br>19,779<br>DKK | |||
| e) | Date<br>of the transaction | 2025-02-05 | |||
| f) | Place<br>of the transaction | AQUIS<br>EXCHANGE EUROPE NON DISPLAY ORDER BOOK (NDOB) |
Novo Nordisk A/SInvestor RelationsNovo Allé 12880 BagsværdDenmarkTelephone:+45 4444 8888www.novonordisk.com
CVR no: 24 25 67 90Company announcement No 8 / 2025
| 1 | Details<br>of the person discharging managerial responsibilities/person closely associated | ||||
|---|---|---|---|---|---|
| a) | Name<br>of the Board member/Executive/Associated Person | Lars<br>Fruergaard Jørgensen | |||
| 2 | Reason<br>for the notification | ||||
| a) | Position/status | President<br>and CEO | |||
| b) | Initial<br>notification/Amendment | Initial<br>notification | |||
| 3 | Details<br>of the issuer | ||||
| a) | Name | Novo<br>Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details<br>of the transaction(s) | ||||
| a) | Description<br>of the financial instrument,<br><br>type<br>of instrument, | Shares | |||
| Identification<br>code | Novo<br>Nordisk B DK0062498333 | ||||
| b) | Nature<br>of the transaction | Sale<br>of shares | |||
| c) | Price(s)<br>and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| 619.48<br>DKK | 1,104<br>shares | ||||
| d) | Aggregated<br>information<br><br>·<br>Aggregated volume<br><br>·<br>Price | 1,104<br>shares<br><br>683,905<br>DKK | |||
| e) | Date<br>of the transaction | 2025-02-05 | |||
| f) | Place<br>of the transaction | AQUIS<br>EXCHANGE EUROPE |
Novo Nordisk A/SInvestor RelationsNovo Allé 12880 BagsværdDenmarkTelephone:+45 4444 8888www.novonordisk.com
CVR no: 24 25 67 90Company announcement No 8 / 2025
| 1 | Details<br>of the person discharging managerial responsibilities/person closely associated | ||||
|---|---|---|---|---|---|
| a) | Name<br>of the Board member/Executive/Associated Person | Lars<br>Fruergaard Jørgensen | |||
| 2 | Reason<br>for the notification | ||||
| a) | Position/status | President<br>and CEO | |||
| b) | Initial<br>notification/Amendment | Initial<br>notification | |||
| 3 | Details<br>of the issuer | ||||
| a) | Name | Novo<br>Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details<br>of the transaction(s) | ||||
| a) | Description<br>of the financial instrument,<br><br>type<br>of instrument, | Shares | |||
| Identification<br>code | Novo<br>Nordisk B DK0062498333 | ||||
| b) | Nature<br>of the transaction | Sale<br>of shares | |||
| c) | Price(s)<br>and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| 617.56<br>DKK | 978<br>shares | ||||
| d) | Aggregated<br>information<br><br>·<br>Aggregated volume<br><br>·<br>Price | 978<br>shares<br><br>603,976<br>DKK | |||
| e) | Date<br>of the transaction | 2025-02-05 | |||
| f) | Place<br>of the transaction | CBOE<br>EUROPE - DXE PERIODIC (NL) |
Novo Nordisk A/SInvestor RelationsNovo Allé 12880 BagsværdDenmarkTelephone:+45 4444 8888www.novonordisk.com
CVR no: 24 25 67 90Company announcement No 8 / 2025
| 1 | Details<br>of the person discharging managerial responsibilities/person closely associated | ||||
|---|---|---|---|---|---|
| a) | Name<br>of the Board member/Executive/Associated Person | Lars<br>Fruergaard Jørgensen | |||
| 2 | Reason<br>for the notification | ||||
| a) | Position/status | President<br>and CEO | |||
| b) | Initial<br>notification/Amendment | Initial<br>notification | |||
| 3 | Details<br>of the issuer | ||||
| a) | Name | Novo<br>Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details<br>of the transaction(s) | ||||
| a) | Description<br>of the financial instrument,<br><br>type<br>of instrument, | Shares | |||
| Identification<br>code | Novo<br>Nordisk B DK0062498333 | ||||
| b) | Nature<br>of the transaction | Sale<br>of shares | |||
| c) | Price(s)<br>and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| 621.01<br>DKK | 42<br>shares | ||||
| d) | Aggregated<br>information<br><br>·<br>Aggregated volume<br><br>·<br>Price | 42 shares<br><br>26,083<br>DKK | |||
| e) | Date<br>of the transaction | 2025-02-05 | |||
| f) | Place<br>of the transaction | CBOE<br>EUROPE - DXE DARK ORDER BOOK (NL) |
Novo Nordisk A/SInvestor RelationsNovo Allé 12880 BagsværdDenmarkTelephone:+45 4444 8888www.novonordisk.com
CVR no: 24 25 67 90Company announcement No 8 / 2025
| 1 | Details<br>of the person discharging managerial responsibilities/person closely associated | ||||
|---|---|---|---|---|---|
| a) | Name<br>of the Board member/Executive/Associated Person | Lars<br>Fruergaard Jørgensen | |||
| 2 | Reason<br>for the notification | ||||
| a) | Position/status | President<br>and CEO | |||
| b) | Initial<br>notification/Amendment | Initial<br>notification | |||
| 3 | Details<br>of the issuer | ||||
| a) | Name | Novo<br>Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details<br>of the transaction(s) | ||||
| a) | Description<br>of the financial instrument,<br><br>type<br>of instrument, | Shares | |||
| Identification<br>code | Novo<br>Nordisk B DK0062498333 | ||||
| b) | Nature<br>of the transaction | Sale<br>of shares | |||
| c) | Price(s)<br>and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| 618.17<br>DKK | 8,331<br>shares | ||||
| d) | Aggregated<br>information<br><br>·<br>Aggregated volume<br><br>·<br>Price | 8,331<br>shares<br><br>5,149,984<br>DKK | |||
| e) | Date<br>of the transaction | 2025-02-05 | |||
| f) | Place<br>of the transaction | CBOE<br>EUROPE - DXE ORDER BOOKS (NL) |
Novo Nordisk A/SInvestor RelationsNovo Allé 12880 BagsværdDenmarkTelephone:+45 4444 8888www.novonordisk.com
CVR no: 24 25 67 90Company announcement No 8 / 2025
| 1 | Details<br>of the person discharging managerial responsibilities/person closely associated | ||||
|---|---|---|---|---|---|
| a) | Name<br>of the Board member/Executive/Associated Person | Lars<br>Fruergaard Jørgensen | |||
| 2 | Reason<br>for the notification | ||||
| a) | Position/status | President<br>and CEO | |||
| b) | Initial<br>notification/Amendment | Initial<br>notification | |||
| 3 | Details<br>of the issuer | ||||
| a) | Name | Novo<br>Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details<br>of the transaction(s) | ||||
| a) | Description<br>of the financial instrument,<br><br>type<br>of instrument, | Shares | |||
| Identification<br>code | Novo<br>Nordisk B DK0062498333 | ||||
| b) | Nature<br>of the transaction | Sale<br>of shares | |||
| c) | Price(s)<br>and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| 618.14<br>DKK | 1,577<br>shares | ||||
| d) | Aggregated<br>information<br><br>·<br>Aggregated volume<br><br>·<br>Price | 1,577<br>shares<br><br>974,805<br>DKK | |||
| e) | Date<br>of the transaction | 2025-02-05 | |||
| f) | Place<br>of the transaction | TURQUOISE<br>EUROPE |
Novo Nordisk A/SInvestor RelationsNovo Allé 12880 BagsværdDenmarkTelephone:+45 4444 8888www.novonordisk.com
CVR no: 24 25 67 90Company announcement No 8 / 2025
| 1 | Details<br>of the person discharging managerial responsibilities/person closely associated | ||||
|---|---|---|---|---|---|
| a) | Name<br>of the Board member/Executive/Associated Person | Lars<br>Fruergaard Jørgensen | |||
| 2 | Reason<br>for the notification | ||||
| a) | Position/status | President<br>and CEO | |||
| b) | Initial<br>notification/Amendment | Initial<br>notification | |||
| 3 | Details<br>of the issuer | ||||
| a) | Name | Novo<br>Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details<br>of the transaction(s) | ||||
| a) | Description<br>of the financial instrument,<br><br>type<br>of instrument, | Shares | |||
| Identification<br>code | Novo<br>Nordisk B DK0062498333 | ||||
| b) | Nature<br>of the transaction | Sale<br>of shares | |||
| c) | Price(s)<br>and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| 618.88<br>DKK | 22,936<br>shares | ||||
| d) | Aggregated<br>information<br><br>·<br>Aggregated volume<br><br>·<br>Price | 22,936<br>shares<br><br>14,194,575<br>DKK | |||
| e) | Date<br>of the transaction | 2025-02-05 | |||
| f) | Place<br>of the transaction | NASDAQ<br>COPENHAGEN A/S |
Novo Nordisk A/SInvestor RelationsNovo Allé 12880 BagsværdDenmarkTelephone:+45 4444 8888www.novonordisk.com
CVR no: 24 25 67 90Company announcement No 8 / 2025
| 1 | Details<br>of the person discharging managerial responsibilities/person closely associated | ||||
|---|---|---|---|---|---|
| a) | Name<br>of the Board member/Executive/Associated Person | Maziar<br>Mike Doustdar | |||
| 2 | Reason<br>for the notification | ||||
| a) | Position/status | Executive<br>Vice President | |||
| b) | Initial<br>notification/Amendment | Initial<br>notification | |||
| 3 | Details<br>of the issuer | ||||
| a) | Name | Novo<br>Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details<br>of the transaction(s) | ||||
| a) | Description<br>of the financial instrument,<br><br>type<br>of instrument, | Shares | |||
| Identification<br>code | Novo<br>Nordisk B DK0062498333 | ||||
| b) | Nature<br>of the transaction | Other<br>transaction (transfer of shares in<br><br>accordance<br>with Long Term Incentive programme) | |||
| c) | Price(s)<br>and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK<br>0.00 | 36,956<br>shares | ||||
| d) | Aggregated<br>information<br><br>·<br>Aggregated volume<br><br>·<br>Price | 36,956<br>shares<br><br>DKK<br>0.00 | |||
| e) | Date<br>of the transaction | 2025-02-05 | |||
| f) | Place<br>of the transaction | Outside<br>a trading venue |
Novo Nordisk A/SInvestor RelationsNovo Allé 12880 BagsværdDenmarkTelephone:+45 4444 8888www.novonordisk.com
CVR no: 24 25 67 90Company announcement No 8 / 2025
| 1 | Details<br>of the person discharging managerial responsibilities/person closely associated | ||||
|---|---|---|---|---|---|
| a) | Name<br>of the Board member/Executive/Associated Person | Maziar<br>Mike Doustdar | |||
| 2 | Reason<br>for the notification | ||||
| a) | Position/status | Executive<br>Vice President | |||
| b) | Initial<br>notification/Amendment | Initial<br>notification | |||
| 3 | Details<br>of the issuer | ||||
| a) | Name | Novo<br>Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details<br>of the transaction(s) | ||||
| a) | Description<br>of the financial instrument,<br><br>type<br>of instrument, | Shares | |||
| Identification<br>code | Novo<br>Nordisk B DK0062498333 | ||||
| b) | Nature<br>of the transaction | Sale<br>of shares | |||
| c) | Price(s)<br>and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK<br>614.55 | 1,852<br>shares | ||||
| d) | Aggregated<br>information<br><br>·<br>Aggregated volume<br><br>·<br>Price | 1,852<br>shares<br><br>DKK<br>1,138,154 | |||
| e) | Date<br>of the transaction | 2025-02-05 | |||
| f) | Place<br>of the transaction | Nasdaq<br>Copenhagen |
Novo Nordisk A/SInvestor RelationsNovo Allé 12880 BagsværdDenmarkTelephone:+45 4444 8888www.novonordisk.com
CVR no: 24 25 67 90Company announcement No 8 / 2025
| 1 | Details<br>of the person discharging managerial responsibilities/person closely associated | ||||
|---|---|---|---|---|---|
| a) | Name<br>of the Board member/Executive/Associated Person | Ludovic<br>Helfgott | |||
| 2 | Reason<br>for the notification | ||||
| a) | Position/status | Executive<br>Vice President | |||
| b) | Initial<br>notification/Amendment | Initial<br>notification | |||
| 3 | Details<br>of the issuer | ||||
| a) | Name | Novo<br>Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details<br>of the transaction(s) | ||||
| a) | Description<br>of the financial instrument,<br><br>type<br>of instrument, | Shares | |||
| Identification<br>code | Novo<br>Nordisk B DK0062498333 | ||||
| b) | Nature<br>of the transaction | Other<br>transaction (transfer of shares in<br><br>accordance<br>with Long Term Incentive programme) | |||
| c) | Price(s)<br>and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK<br>0.00 | 27,765<br>shares | ||||
| d) | Aggregated<br>information<br><br>·<br>Aggregated volume<br><br>·<br>Price | 27,765<br>shares<br><br>DKK<br>0.00 | |||
| e) | Date<br>of the transaction | 2025-02-05 | |||
| f) | Place<br>of the transaction | Outside<br>a trading venue |
Novo Nordisk A/SInvestor RelationsNovo Allé 12880 BagsværdDenmarkTelephone:+45 4444 8888www.novonordisk.com
CVR no: 24 25 67 90Company announcement No 8 / 2025
| 1 | Details<br>of the person discharging managerial responsibilities/person closely associated | ||||
|---|---|---|---|---|---|
| a) | Name<br>of the Board member/Executive/Associated Person | Ludovic<br>Helfgott | |||
| 2 | Reason<br>for the notification | ||||
| a) | Position/status | Executive<br>Vice President | |||
| b) | Initial<br>notification/Amendment | Initial<br>notification | |||
| 3 | Details<br>of the issuer | ||||
| a) | Name | Novo<br>Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details<br>of the transaction(s) | ||||
| a) | Description<br>of the financial instrument,<br><br>type<br>of instrument, | Shares | |||
| Identification<br>code | Novo<br>Nordisk B DK0062498333 | ||||
| b) | Nature<br>of the transaction | Sale<br>of shares | |||
| c) | Price(s)<br>and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK<br>614.55 | 8,990<br>shares | ||||
| d) | Aggregated<br>information<br><br>·<br>Aggregated volume<br><br>·<br>Price | 8,990<br>shares<br><br>DKK<br>5,524,840 | |||
| e) | Date<br>of the transaction | 2025-02-05 | |||
| f) | Place<br>of the transaction | Nasdaq<br>Copenhagen |
Novo Nordisk A/SInvestor RelationsNovo Allé 12880 BagsværdDenmarkTelephone:+45 4444 8888www.novonordisk.com
CVR no: 24 25 67 90Company announcement No 8 / 2025
| 1 | Details<br>of the person discharging managerial responsibilities/person closely associated | ||||
|---|---|---|---|---|---|
| a) | Name<br>of the Board member/Executive/Associated Person | Ludovic<br>Helfgott | |||
| 2 | Reason<br>for the notification | ||||
| a) | Position/status | Executive<br>Vice President | |||
| b) | Initial<br>notification/Amendment | Initial<br>notification | |||
| 3 | Details<br>of the issuer | ||||
| a) | Name | Novo<br>Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details<br>of the transaction(s) | ||||
| a) | Description<br>of the financial instrument,<br><br>type<br>of instrument, | Shares | |||
| Identification<br>code | Novo<br>Nordisk B DK0062498333 | ||||
| b) | Nature<br>of the transaction | Sale<br>of shares | |||
| c) | Price(s)<br>and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK<br>617.00 | 12,000<br>shares | ||||
| d) | Aggregated<br>information<br><br>·<br>Aggregated volume<br><br>·<br>Price | 12,000<br>shares<br><br>DKK<br>7,404,000 | |||
| e) | Date<br>of the transaction | 2025-02-06 | |||
| f) | Place<br>of the transaction | Nasdaq<br>Copenhagen |
Novo Nordisk A/SInvestor RelationsNovo Allé 12880 BagsværdDenmarkTelephone:+45 4444 8888www.novonordisk.com
CVR no: 24 25 67 90Company announcement No 8 / 2025
| 1 | Details<br>of the person discharging managerial responsibilities/person closely associated | ||||
|---|---|---|---|---|---|
| a) | Name<br>of the Board member/Executive/Associated Person | Karsten<br>Munk Knudsen | |||
| 2 | Reason<br>for the notification | ||||
| a) | Position/status | Executive<br>Vice President | |||
| b) | Initial<br>notification/Amendment | Initial<br>notification | |||
| 3 | Details<br>of the issuer | ||||
| a) | Name | Novo<br>Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details<br>of the transaction(s) | ||||
| a) | Description<br>of the financial instrument,<br><br>type<br>of instrument, | Shares | |||
| Identification<br>code | Novo<br>Nordisk B DK0062498333 | ||||
| b) | Nature<br>of the transaction | Other<br>transaction (transfer of shares in<br><br>accordance<br>with Long Term Incentive programme) | |||
| c) | Price(s)<br>and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK<br>0.00 | 30,728<br>shares | ||||
| d) | Aggregated<br>information<br><br>·<br>Aggregated volume<br><br>·<br>Price | 30,728<br>shares<br><br>DKK<br>0.00 | |||
| e) | Date<br>of the transaction | 2025-02-05 | |||
| f) | Place<br>of the transaction | Outside<br>a trading venue |
Novo Nordisk A/SInvestor RelationsNovo Allé 12880 BagsværdDenmarkTelephone:+45 4444 8888www.novonordisk.com
CVR no: 24 25 67 90Company announcement No 8 / 2025
| 1 | Details<br>of the person discharging managerial responsibilities/person closely associated | ||||
|---|---|---|---|---|---|
| a) | Name<br>of the Board member/Executive/Associated Person | Martin<br>Holst Lange | |||
| 2 | Reason<br>for the notification | ||||
| a) | Position/status | Executive<br>Vice President | |||
| b) | Initial<br>notification/Amendment | Initial<br>notification | |||
| 3 | Details<br>of the issuer | ||||
| a) | Name | Novo<br>Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details<br>of the transaction(s) | ||||
| a) | Description<br>of the financial instrument,<br><br>type<br>of instrument, | Shares | |||
| Identification<br>code | Novo<br>Nordisk B DK0062498333 | ||||
| b) | Nature<br>of the transaction | Other<br>transaction (transfer of shares in<br><br>accordance<br>with Long Term Incentive programme) | |||
| c) | Price(s)<br>and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK<br>0.00 | 30,728<br>shares | ||||
| d) | Aggregated<br>information<br><br>·<br>Aggregated volume<br><br>·<br>Price | 30,728<br>shares<br><br>DKK<br>0.00 | |||
| e) | Date<br>of the transaction | 2025-02-05 | |||
| f) | Place<br>of the transaction | Outside<br>a trading venue |
Novo Nordisk A/SInvestor RelationsNovo Allé 12880 BagsværdDenmarkTelephone:+45 4444 8888www.novonordisk.com
CVR no: 24 25 67 90Company announcement No 8 / 2025
| 1 | Details<br>of the person discharging managerial responsibilities/person closely associated | ||||
|---|---|---|---|---|---|
| a) | Name<br>of the Board member/Executive/Associated Person | Tania<br>Sabroe | |||
| 2 | Reason<br>for the notification | ||||
| a) | Position/status | Executive<br>Vice President | |||
| b) | Initial<br>notification/Amendment | Initial<br>notification | |||
| 3 | Details<br>of the issuer | ||||
| a) | Name | Novo<br>Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details<br>of the transaction(s) | ||||
| a) | Description<br>of the financial instrument,<br><br>type<br>of instrument, | Shares | |||
| Identification<br>code | Novo<br>Nordisk B DK0062498333 | ||||
| b) | Nature<br>of the transaction | Other<br>transaction (transfer of shares in<br><br>accordance<br>with Long Term Incentive programme) | |||
| c) | Price(s)<br>and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK<br>0.00 | 10,561<br>shares | ||||
| d) | Aggregated<br>information<br><br>·<br>Aggregated volume<br><br>·<br>Price | 10,561<br>shares<br><br>DKK<br>0.00 | |||
| e) | Date<br>of the transaction | 2025-02-05 | |||
| f) | Place<br>of the transaction | Outside<br>a trading venue |
Novo Nordisk A/SInvestor RelationsNovo Allé 12880 BagsværdDenmarkTelephone:+45 4444 8888www.novonordisk.com
CVR no: 24 25 67 90Company announcement No 8 / 2025
| 1 | Details<br>of the person discharging managerial responsibilities/person closely associated | ||||
|---|---|---|---|---|---|
| a) | Name<br>of the Board member/Executive/Associated Person | Marcus<br>Schindler | |||
| 2 | Reason<br>for the notification | ||||
| a) | Position/status | Executive<br>Vice President | |||
| b) | Initial<br>notification/Amendment | Initial<br>notification | |||
| 3 | Details<br>of the issuer | ||||
| a) | Name | Novo<br>Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details<br>of the transaction(s) | ||||
| a) | Description<br>of the financial instrument,<br><br>type<br>of instrument, | Shares | |||
| Identification<br>code | Novo<br>Nordisk B DK0062498333 | ||||
| b) | Nature<br>of the transaction | Other<br>transaction (transfer of shares in<br><br>accordance<br>with Long Term Incentive programme) | |||
| c) | Price(s)<br>and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK<br>0.00 | 30,728<br>shares | ||||
| d) | Aggregated<br>information<br><br>·<br>Aggregated volume<br><br>·<br>Price | 30,728<br>shares<br><br>DKK<br>0.00 | |||
| e) | Date<br>of the transaction | 2025-02-05 | |||
| f) | Place<br>of the transaction | Outside<br>a trading venue |
Novo Nordisk A/SInvestor RelationsNovo Allé 12880 BagsværdDenmarkTelephone:+45 4444 8888www.novonordisk.com
CVR no: 24 25 67 90Company announcement No 8 / 2025
| 1 | Details<br>of the person discharging managerial responsibilities/person closely associated | ||||
|---|---|---|---|---|---|
| a) | Name<br>of the Board member/Executive/Associated Person | Camilla<br>Sylvest | |||
| 2 | Reason<br>for the notification | ||||
| a) | Position/status | Executive<br>Vice President | |||
| b) | Initial<br>notification/Amendment | Initial<br>notification | |||
| 3 | Details<br>of the issuer | ||||
| a) | Name | Novo<br>Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details<br>of the transaction(s) | ||||
| a) | Description<br>of the financial instrument,<br><br>type<br>of instrument, | Shares | |||
| Identification<br>code | Novo<br>Nordisk B DK0062498333 | ||||
| b) | Nature<br>of the transaction | Other<br>transaction (transfer of shares in<br><br>accordance<br>with Long Term Incentive programme) | |||
| c) | Price(s)<br>and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK<br>0.00 | 30,728<br>shares | ||||
| d) | Aggregated<br>information<br><br>·<br>Aggregated volume<br><br>·<br>Price | 30,728<br>shares<br><br>DKK<br>0.00 | |||
| e) | Date<br>of the transaction | 2025-02-05 | |||
| f) | Place<br>of the transaction | Outside<br>a trading venue |
Novo Nordisk A/SInvestor RelationsNovo Allé 12880 BagsværdDenmarkTelephone:+45 4444 8888www.novonordisk.com
CVR no: 24 25 67 90Company announcement No 8 / 2025
| 1 | Details<br>of the person discharging managerial responsibilities/person closely associated | ||||
|---|---|---|---|---|---|
| a) | Name<br>of the Board member/Executive/Associated Person | Camilla<br>Sylvest | |||
| 2 | Reason<br>for the notification | ||||
| a) | Position/status | Executive<br>Vice President | |||
| b) | Initial<br>notification/Amendment | Initial<br>notification | |||
| 3 | Details<br>of the issuer | ||||
| a) | Name | Novo<br>Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details<br>of the transaction(s) | ||||
| a) | Description<br>of the financial instrument,<br><br>type<br>of instrument, | Shares | |||
| Identification<br>code | Novo<br>Nordisk B DK0062498333 | ||||
| b) | Nature<br>of the transaction | Sale<br>of shares | |||
| c) | Price(s)<br>and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK<br>615.00 | 15,364<br>shares | ||||
| d) | Aggregated<br>information<br><br>·<br>Aggregated volume<br><br>·<br>Price | 15.364<br>shares<br><br>DKK<br>9,448,860 | |||
| e) | Date<br>of the transaction | 2025-02-05 | |||
| f) | Place<br>of the transaction | Nasdaq<br>Copenhagen |
Novo Nordisk A/SInvestor RelationsNovo Allé 12880 BagsværdDenmarkTelephone:+45 4444 8888www.novonordisk.com
CVR no: 24 25 67 90Company announcement No 8 / 2025
| 1 | Details<br>of the person discharging managerial responsibilities/person closely associated | ||||
|---|---|---|---|---|---|
| a) | Name<br>of the Board member/Executive/Associated Person | Henrik<br>Ehlers Wulff | |||
| 2 | Reason<br>for the notification | ||||
| a) | Position/status | Executive<br>Vice President | |||
| b) | Initial<br>notification/Amendment | Initial<br>notification | |||
| 3 | Details<br>of the issuer | ||||
| a) | Name | Novo<br>Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details<br>of the transaction(s) | ||||
| a) | Description<br>of the financial instrument,<br><br>type<br>of instrument, | Shares | |||
| Identification<br>code | Novo<br>Nordisk B DK0062498333 | ||||
| b) | Nature<br>of the transaction | Other<br>transaction (transfer of shares in<br><br>accordance<br>with Long Term Incentive programme) | |||
| c) | Price(s)<br>and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK<br>0.00 | 32,448<br>shares | ||||
| d) | Aggregated<br>information<br><br>·<br>Aggregated volume<br><br>·<br>Price | 32,448<br>shares<br><br>DKK<br>0.00 | |||
| e) | Date<br>of the transaction | 2025-02-05 | |||
| f) | Place<br>of the transaction | Outside<br>a trading venue |
Novo Nordisk A/SInvestor RelationsNovo Allé 12880 BagsværdDenmarkTelephone:+45 4444 8888www.novonordisk.com
CVR no: 24 25 67 90Company announcement No 8 / 2025
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
Media: Ambre James-Brown+45 3079 [email protected]Liz Skrbkova (US)+1 609 917 [email protected]Investors: Jacob Martin Wiborg Rode+45 3075 [email protected]David Heiberg Landsted+45 3077 [email protected]Sina Meyer+45 3079 [email protected]Ida Schaap Melvold+45 3077 [email protected]Max Ung+45 3077 [email protected]Frederik Taylor Pitter+1 609 613 [email protected]
Novo Nordisk A/SInvestor RelationsNovo Allé 12880 BagsværdDenmarkTelephone:+45 4444 8888www.novonordisk.com
CVR no: 24 25 67 90Company announcement No 8 / 2025
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: February 6, 2025 | NOVO NORDISK A/S<br><br>Lars Fruergaard Jørgensen<br><br>Chief Executive Officer |
|---|